901
Views
24
CrossRef citations to date
0
Altmetric
Complex medical dermatology

Biologic and small-molecule medications in the management of pyoderma gangrenosum

, , , &
Pages 264-276 | Received 11 Jul 2018, Accepted 26 Jul 2018, Published online: 07 Sep 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Qianqian Zhou, Shengru Zhou, Huizi Xiong, Jianqiu Yang, Ziliang Yang, Naihui Zhou, Jinzhu Mao & Min Li. (2023) A Case of Paradoxical Reactions to Biologic Therapy for Psoriasis. Clinical, Cosmetic and Investigational Dermatology 16, pages 1493-1497.
Read now
Liang Joo Leow & Nicolas Zubrzycki. (2022) Recalcitrant Ulcerative Pyoderma Gangrenosum of the Leg Responsive to Tildrakizumab: A Case Report. Clinical, Cosmetic and Investigational Dermatology 15, pages 1729-1736.
Read now
Justin D. Lu, Milica Milakovic, Alex G. Ortega-Loayza, Angelo V. Marzano & Afsaneh Alavi. (2020) Pyoderma gangrenosum: proposed pathogenesis and current use of biologics with an emphasis on complement C5a inhibitor IFX-1. Expert Opinion on Investigational Drugs 29:11, pages 1179-1185.
Read now
Mohamad Goldust, Erika L. Hagstrom, Dipali Rathod & Alex G. Ortega-Loayza. (2020) Diagnosis and novel clinical treatment strategies for pyoderma gangrenosum. Expert Review of Clinical Pharmacology 13:2, pages 157-161.
Read now

Articles from other publishers (20)

Keiichi Yamanaka. (2023) New treatment of pyoderma gangrenosum and hidradenitis suppurativa: A review. The Journal of Dermatology.
Crossref
Olivia M. Haddadin, Michael E. Jacobson, Diana M. Chen, David O. Croitoru, Joachim Dissemond, Joao Renato V. Gontijo, Philip J. Hampton, Robert I. Kelly, Angelo Valerio Marzano, Yayoi Tada, Louise A. A. Gerbens & Alex G. Ortega-Loayza. (2023) Minimum data set for treatment effectiveness in pyoderma gangrenosum (MIDSTEP): an international protocol of an e-Delphi study to develop a clinical physician-driven treatment effectiveness registry on behalf of the UPGRADE initiative. Archives of Dermatological Research 315:10, pages 2913-2919.
Crossref
Elif Afacan Yıldırım, Yusuf Can Edek & Esra Adısen. (2023) The Clinical Characteristics of Patients With Pyoderma Gangrenosum in a Tertiary Referral Hospital: A Retrospective Cohort Study. The International Journal of Lower Extremity Wounds.
Crossref
Joachim Dissemond, Angelo V. Marzano, Philip J. Hampton & Alex G. Ortega-Loayza. (2023) Pyoderma Gangrenosum: Treatment Options. Drugs 83:14, pages 1255-1267.
Crossref
Giammarco Granieri, Alessandra Michelucci, Flavia Manzo Margiotta, Bianca Cei, Saverio Vitali, Marco Romanelli & Valentina Dini. (2023) The Role of Ultra-High-Frequency Ultrasound in Pyoderma Gangrenosum: New Insights in Pathophysiology and Diagnosis. Diagnostics 13:17, pages 2802.
Crossref
Vanitha Agrahara Sathyanarayana, Debaditya Roy, Bhavya Nagaraju & Vijay K. R. Rao. (2023) Tofacitinib in pyoderma gangrenosum – A case series. International Journal of Rheumatic Diseases.
Crossref
Salha Hakami, Yousef Alharthi & Abeer Mohammed M Alanazi. (2022) Refractory Pyoderma Gangrenosum: Stabilized on Colchicine and Tumor Necrosis Factor (TNF) Inhibitor. Cureus.
Crossref
Carlo Alberto Maronese, Matthew A. Pimentel, May M. Li, Giovanni Genovese, Alex G. Ortega-Loayza & Angelo Valerio Marzano. (2022) Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments. American Journal of Clinical Dermatology 23:5, pages 615-634.
Crossref
Niloofar Khoshnam-Rad, Azin Gheymati & Zahra Jahangard-Rafsanjani. (2021) Tyrosine kinase inhibitors-associated pyoderma gangrenosum, a systematic review of published case reports. Anti-Cancer Drugs 33:1, pages e1-e8.
Crossref
Laura Carolina Camacho-Pérez & Juan Raúl Castro-Ayarza. (2021) Pioderma gangrenoso. Piel 36:9, pages 594-601.
Crossref
Aleksandra Opalińska, Dominika Kwiatkowska, Adrian Burdacki, Mirosław Markiewicz, Dominik Samotij, Marek Dudziński, Jadwiga Niemiec-Dudek, Elżbieta Ostańska & Adam Reich. (2021) Multifocal Pyoderma Gangrenosum with an Underlying Hemophagocytic Lymphohistiocytosis: Case Report and the Review of the Literature. Dermatology and Therapy 11:4, pages 1217-1237.
Crossref
Delice Kayishunge, Jonathan Rick, Aadil Ahmed, Tara Akunna & Henry Wong. (2021) Progression of pyoderma gangrenosum with angioinvasive fungus. JAAD Case Reports 11, pages 41-43.
Crossref
Dean J. Choong, Jeremy L. Ng & Carl Vinciullo. (2021) Pyoderma gangrenosum associated with Takayasu's arteritis in a young Caucasian woman and response to biologic therapy with tocilizumab. JAAD Case Reports 9, pages 4-6.
Crossref
Morton Scheinberg, Luis Antônio Machado, Luiz Guilherme M Castro, Sineida Berbert Ferreira & Nilceo Michalany. (2021) Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor. Journal of Translational Autoimmunity 4, pages 100099.
Crossref
Joanne S Jacob & Philip R Cohen. (2020) Concurrent Scleredema and Pyoderma Gangrenosum: Case Report and Review of Comorbid Conditions. Cureus.
Crossref
Michael W. Tee, Andrew B. Avarbock, Jonathan Ungar & John W. Frew. (2020) Rapid resolution of pyoderma gangrenosum with brodalumab therapy. JAAD Case Reports 6:11, pages 1167-1169.
Crossref
Andrea De Pascalis & Valentina Dini. 2020. Technology in Practical Dermatology. Technology in Practical Dermatology 465 472 .
A.C. Pilz, A. Zink, R. Franz, T. Biedermann & S.M.C. Möckel. (2019) Pyoderma gangrenosum in a patient with lipoid proteinosis (Urbach–Wiethe disease). Journal of the European Academy of Dermatology and Venereology 33:8.
Crossref
Josh Fletcher, Raed Alhusayen & Afsaneh Alavi. (2019) Recent advances in managing and understanding pyoderma gangrenosum. F1000Research 8, pages 2092.
Crossref
Massimo Papi & Claudia Papi. (2018) Biologics in Microangiopathic Wounds. The International Journal of Lower Extremity Wounds 17:4, pages 205-213.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.